NCT07205159Phase 1Recruiting
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
A Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Recruiting
- Declared phase
- Phase 1
- Sponsor
- Forte Biosciences, Inc.
- Participants (registry)
- 32
- Start
- October 2025
- Primary completion
- March 2027 (planned)
- Study completion
- March 2027 (planned)
- Last registry update
- November 2025
- Countries
- Australia, New Zealand
Conditions studied: Alopecia Areata
Interventions: FB102, Placebo
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.